Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

Fast approval doesnt always mean the right fit #shorts

1 Feb 2026 · 0 min

Watch on YouTube

0:28

In this YouTube short, the speaker critiques the FDA's fast‑track approval pathway for cancer drugs, arguing that it allows new therapies to be approved without needing to be substantially better than existing options. The commentator highlights that these fast‑tracked drugs are often far more expensive, provide only modest extensions of life—sometimes just a few months—and generally manage cancer rather than achieving full remission. He also suggests that this dynamic fuels a larger "cancer industrial complex" pipeline, increasing costs without delivering proportionate health benefits, and directs viewers to his other videos for further discussion.

If we go back and look at these drugs the way they're approved, this is how it's done. Big pharma does fast track with fda, means it gets it approved, sometimes faster. The drug doesn't have to be much better than an existing drug on the market. It's much more expensive. It's managing the cancer, often not bringing it into full remission like we want. And then this gets moved on down the pipeline of the cancer industrial complex. You may want to watch my other videos to learn about those. And it increases the cost, but only improves life expectancy, maybe by a few months.